Home
Corporate
News
Investors
Technology
Patient Resources
Commercial
Contact Us
Click here for details of Bradmer's
Phase III Trial for GBM Patients
CLICK HERE
for webcast and slides.
Bradmer Announces 2009 First Quarter Operational And Financial Results
Bradmer Announces 2008 Fourth Quarter And Fiscal Year Operational And Financial Results
Bradmer Implements Cash Conservation Plan
Bradmer Provides Clinical Trial Update And Announces Evaluation Of Strategic Alternatives
RBC Capital Markets 2008 Healthcare Conference
Antibody Strategies for Fighting Cancer
Alan M. Ezrin, PhD, panelist
December 10, 2008, 3:30pm ET
Live audio webcast
>>
listen here
Bradmer Initiates Enrollment In Phase III GLASS-ART Trial In Primary Glioblastoma Multiforme
Bradmer Reports Progression Free Survival Data From Previous Phase II Glioblastoma Multiforme Trials
- PFS data from Neuradiab™ compares favorably to data from other technologies -
Learn More
Toronto Stock Exchange:
BMR
Click here for current stock info
© 2005 - 2008 Bradmer Pharmaceuticals
Forward-Looking Statements
|
Terms and Conditions of Use
